TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) released new data that confirm that leukemia-free survival (LFS) is a valid surrogate endpoint for overall survival (OS) in Acute Myeloid Leukemia (AML) patients in complete remission. These findings are based on an analysis of data from the Phase III trial of Ceplene, EpiCept’s product candidate for the remission maintenance and prevention of relapse in patients with AML in first remission. This data is being presented at the European Hematology Association’s (EHA) 13th Congress in Copenhagen, Denmark.
